<DOC>
	<DOC>NCT02193074</DOC>
	<brief_summary>The primary objective of the study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally (IT) to participants with infantile-onset SMA. The secondary objective of the study is to examine the safety and tolerability of nusinersen administered intrathecally to participants with infantile-onset SMA.</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy</brief_title>
	<detailed_description>This study was conducted and the protocol was registered by Ionis Pharmaceuticals, Inc.. In August 2016, sponsorship of the trial was transferred to Biogen.</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy, Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Be born (gestational age) between 37 and 42 weeks Be medically diagnosed with spinal muscular atrophy (SMA) Have Survival Motor Neuron2 (SMN2) Copy number = 2 Body weight equal to or greater than 3rd percentile for age using appropriate countryspecific guidelines Be able to follow all study procedures Reside within approximately 9 hours groundtravel distance from a participating study center, for the duration of the study Key Hypoxemia Oxygen (O2) saturation awake less than 96% or O2 saturation asleep less than 96%, without ventilation support) during screening evaluation Clinically significant abnormalities in hematology or clinical chemistry parameters or Electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit that would render the participant unsuitable for participation in the study Participant's parent or legal guardian is not willing to meet standard of care guidelines (including vaccinations and respiratory syncytial virus prophylaxis if available), nor provide nutritional and respiratory support throughout the study NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>210 Days</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS-SMN Rx</keyword>
	<keyword>ISIS 396443</keyword>
	<keyword>IONIS-SMNRx</keyword>
	<keyword>IONIS-SMN Rx</keyword>
	<keyword>Spinraza</keyword>
	<keyword>ENDEAR</keyword>
</DOC>